Immediate Diagnostic Confirmation and Assessment of Acute Hepatitis B
For a suspected acute hepatitis B case with ALT 2500 IU/L, immediately confirm the diagnosis with HBsAg and IgM anti-HBc testing, assess liver synthetic function (bilirubin, albumin, prothrombin time/INR), and provide supportive care while monitoring closely for signs of hepatic decompensation. 1
Initial Diagnostic Workup
The markedly elevated ALT of 2500 IU/L suggests acute hepatic injury. Your immediate priorities are:
Serologic confirmation:
- HBsAg - confirms active HBV infection
- IgM anti-HBc - distinguishes acute from chronic infection (present in acute, absent in chronic) 1
- If HBsAg is negative on follow-up testing, the patient likely had a transient acute infection 1
Liver function assessment:
- AST, bilirubin, albumin, prothrombin time/INR 1
- These determine severity and risk of progression to fulminant hepatitis
- Critical threshold: INR >1.5 or total bilirubin >3 mg/dL indicates impaired synthetic function and potential liver failure 2
Clinical Severity Stratification
Assess for signs of severe acute hepatitis or fulminant hepatitis:
- Jaundice with coagulopathy (INR >1.5)
- Encephalopathy
- Ascites
- Total bilirubin >3 mg/dL 2
If any of these are present, immediate hospital admission is required; if fulminant hepatitis develops, transfer to ICU and evaluate urgently for liver transplantation 3.
Management Approach
For uncomplicated acute hepatitis B (>95% of adult cases):
No specific antiviral therapy is indicated for typical acute hepatitis B, as spontaneous resolution occurs in >95% of immunocompetent adults 4, 3. Management consists of:
- Supportive care: relative rest, hypercaloric diet 3
- Outpatient monitoring if stable (no coagulopathy, bilirubin <3 mg/dL, no encephalopathy)
- Serial ALT and liver function tests every 1-2 weeks initially
- Repeat HBsAg at 6 months to confirm clearance and rule out progression to chronic infection 1
For severe acute hepatitis (jaundice with coagulopathy):
- Hospital admission for intensive monitoring 3
- Daily assessment of mental status, INR, bilirubin
- Consider early antiviral therapy (entecavir or tenofovir) if evidence of hepatic decompensation, though data are limited 5
- Urgent transplant evaluation if INR >1.5 persists or worsens, encephalopathy develops, or bilirubin continues rising 3, 5
Critical Pitfalls to Avoid
Do not delay assessment of severity. With ALT 2500 IU/L, you must immediately check synthetic function markers. An elevated ALT alone does not predict outcome—coagulopathy and hyperbilirubinemia are the danger signs 5.
Do not assume all cases resolve spontaneously. While rare in adults, progression to chronic infection occurs in approximately 5% of cases, and fulminant hepatitis occurs in 0.5-1.5% 6, 4. The 6-month follow-up HBsAg is mandatory 1.
Do not start routine antiviral therapy in uncomplicated cases. There is no evidence that antivirals reduce severity or prevent chronicity in typical acute hepatitis B 3. Reserve antivirals for severe cases with hepatic decompensation 5.
Follow-Up Protocol
If HBsAg persists at 6 months:
- Diagnose as chronic hepatitis B
- Perform complete evaluation: HBeAg, anti-HBe, HBV DNA, assess for cirrhosis 1
- Initiate antiviral therapy if HBV DNA >2,000 IU/mL with elevated ALT or evidence of significant fibrosis 7, 4
Public health measures:
- Screen and vaccinate household contacts and sexual partners (test for anti-HBc; vaccinate if susceptible) 1
- Report case to local health department 1
- Counsel patient on preventing transmission (no blood/organ donation, avoid sharing razors/toothbrushes, inform healthcare providers of status) 1
Monitoring Timeline
- Weeks 1-4: ALT, bilirubin, INR every 1-2 weeks
- Month 6: Repeat HBsAg to confirm clearance
- If HBsAg negative at 6 months: infection resolved, no further HBV-specific follow-up needed
- If HBsAg positive at 6 months: transition to chronic hepatitis B management protocol 1